U.S. Markets open in 7 hrs 58 mins
  • S&P Futures

    4,163.25
    -20.25 (-0.48%)
     
  • Dow Futures

    34,583.00
    -85.00 (-0.25%)
     
  • Nasdaq Futures

    13,244.50
    -112.25 (-0.84%)
     
  • Russell 2000 Futures

    2,189.10
    -20.50 (-0.93%)
     
  • Crude Oil

    64.37
    -0.55 (-0.85%)
     
  • Gold

    1,837.20
    -0.40 (-0.02%)
     
  • Silver

    27.28
    -0.19 (-0.71%)
     
  • EUR/USD

    1.2148
    +0.0013 (+0.1093%)
     
  • 10-Yr Bond

    1.6020
    0.0000 (0.00%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4129
    +0.0008 (+0.0537%)
     
  • USD/JPY

    108.8210
    -0.0200 (-0.0184%)
     
  • BTC-USD

    54,986.29
    -4,013.83 (-6.80%)
     
  • CMC Crypto 200

    1,452.56
    -108.74 (-6.96%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,605.11
    -913.19 (-3.09%)
     

What Type Of Shareholders Make Up Advanced Oncotherapy plc's (LON:AVO) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Advanced Oncotherapy plc (LON:AVO) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

With a market capitalization of UK£145m, Advanced Oncotherapy is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Advanced Oncotherapy.

See our latest analysis for Advanced Oncotherapy

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Advanced Oncotherapy?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Advanced Oncotherapy. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Advanced Oncotherapy's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Advanced Oncotherapy. Liquid Harmony Ltd is currently the company's largest shareholder with 13% of shares outstanding. With 8.7% and 8.1% of the shares outstanding respectively, Seamus Mulligan and Céleste Management SA are the second and third largest shareholders. Furthermore, CEO Nicolas Serandour is the owner of 0.5% of the company's shares.

We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.

Insider Ownership Of Advanced Oncotherapy

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that insiders maintain a significant holding in Advanced Oncotherapy plc. It has a market capitalization of just UK£145m, and insiders have UK£30m worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

General Public Ownership

With a 11% ownership, the general public have some degree of sway over Advanced Oncotherapy. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

It seems that Private Companies own 34%, of the Advanced Oncotherapy stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Advanced Oncotherapy (of which 1 is concerning!) you should know about.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.